Cryo-Cell International, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Income per Common Share

Income per Common Share

6 Months Ended

May 31, 2017

Earnings Per Share [Abstract]

Income per Common Share

Note 7 – Income per Common Share

The following table sets forth the calculation of basic and diluted net income per common share:


	Three Months Ended				Six Months Ended
	May 31, 2017		May 31, 2016		May 31, 2017		May 31, 2016
Numerator:
Net Income	$	496,940	$	637,132	$	983,863	$	514,196

Denominator:
Weighted-average shares outstanding-basic		7,144,775		9,087,807		7,024,280		9,029,909
Dilutive common shares issuable upon exercise of stock options		581,785		309,423		558,255		306,629

Weighted-average shares-diluted		7,726,560		9,397,230		7,582,535		9,336,538

Net income per common share:
Basic	$	0.07	$	0.07	$	0.14	$	0.06

Diluted	$	0.06	$	0.07	$	0.13	$	0.06

For the three and six months ended May 31, 2017, the Company included the effect of all outstanding options in the computation of diluted earnings per share, as all of the outstanding stock options were in the money.

For the three and six months ended May 31, 2016, the Company excluded the effect of 40,000 and 40,000, respectively, outstanding options from the computation of diluted earnings per share, as the effect of potentially dilutive shares from the outstanding stock options would be anti-dilutive.